With the year coming to an end we put together an overview of the many developments in breast cancer research and treatment from 2018.
The American Society of Breast Surgeons (ASBrS) united thought leaders, payment and reimbursement experts, and Industry Relations Council members to develop a strategic approach to prepare its physician members to lead enhancements in breast cancer surgery, therapeutics and technology for the future.
At the HBA: Diary of a Leader event, Lori Chmura addressed bridging the gender gap in leadership at the executive level within the healthcare industry.
“I think for breast cancer, every few months there's something new and exciting,” the physician shared. “I think there's always some new technology, new drugs, or new study that comes out that changes our outlook."
“I realized breast surgery put me in the operating room, which I love to do, but it also allowed me to take care of my patients hands-on and I could follow my patients practically forever,” explained Dr. Karen Karsif.
The team at Dune Medical is heartbroken over the passing of Nancy M. Cappello, Ph.D. and would like to extend sincere condolences to her family, especially her husband Joseph Cappello, friends, colleagues, and supporters.
Lori Chmura, CEO of Dune Medical Devices, maker of the successful MarginProbe device is scheduled to present at the Canaccord Genuity Medical Technologies and Diagnostics Forum on Thursday, November 15th at 2:30 p.m. EST at the Westin Grand Central in New York, NY.
In alignment with their mission to ensure that every woman with a diagnosis of breast cancer has an opportunity to receive the most comprehensive care possible, Dune Medical recently sponsored SHARE at their annual tasting benefit night, A Second Helping of Life.
Dr. Jeffrey Falk, board certified Surgical Oncologist at St Johns Hospital in Detroit, recently shared his outstanding results reducing positive margin rates using MarginProbe in lumpectomy at ORBS by Design 2018.
Breast density is one of the most common reasons for failure of mammography to detect cancer and presents unique challenges for breast cancer patients and providers. Despite being a well-established independent risk factor for breast cancer(1), 95% of women do not know their breast density.